Akorn, Inc. (AKRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
24.45-0.33 (-1.33%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close24.78
Bid23.19 x 100
Ask24.99 x 1000
Day's Range23.81 - 24.72
52wk Range17.57 - 39.46
1y Target EstN/A
Market Cap3.08B
P/E Ratio (ttm)16.48
Avg Vol (3m)1,184,201
Dividend & Yield0.00 (0.00%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Business Wire6 hours ago

    Robbins Arroyo LLP: Akorn, Inc. (AKRX) Misled Shareholders According to a Recently Filed Class Action

    Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Akorn, Inc. in the U.S. District Court for the Southern District of New York.

  • Barrons.com4 days ago

    Valeant Pharmaceuticals: Stay Far Away, JPMorgan Says

    In a report looking ahead to earnings from specialty pharmaceutical companies like Allergan (AGN), and Endo International (ENDP), JPMorgan's Chris Schott and team call Valeant Pharmaceuticals International (VRX) a name to "avoid." They explain why: Ahead of 3Q EPS results, we wanted to share our latest thoughts on our Specialty Pharma group. For names we would own into 3Q, we would highlight Allergan, Endo International and Akorn (AKRX) and would avoid Valeant and Impax Laboratories (IPXL), where we see risk to guidance given the implied steep 2H ramp... Valeant: Remain cautious into a widely expected guidance cut.

  • Investopedia7 days ago

    Akorn Plant Cited For 6 FDA Violations (AKRX)

    Akorn Inc. was slapped with a warning letter after the FDA found 6 quality-control violations at its Decatur, Illinois, drug manufacturing plant.